Worth reading
61In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
-3504
¥ millionWording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPNet Sales19,974¥ millionYear on year -6.5%Progress 43.7%
Operating profit-3,504¥ million
Ordinary income-3,798¥ million
Net income attributable to owners of the parent-3,867¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share-¥31.67
Financial position at period-end
Total assets113,876¥ million
of which net assets 41,389 ¥ millionEquity ratio 35.9%vs. prior year-end -7.0pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating-3,804
Investment-8,267
Financials+8,524
Net change-3,547
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥10,435 million
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥45,700 million (YoY +13.3%)
Operating profit¥1,100 million (YoY +98.2%)
Ordinary income¥500 million (YoY -57.1%)
Net income¥200 million (YoY -90.8%)
Revision to Earnings ForecastNo
Annual Dividend Forecast20 Yen → 20 Yen（0.0%）
Factors Behind Changes in Business Performance
Lower contract revenue, lower revenue from Growject, and a 30.6% increase in research and development expenses. Meanwhile, IZCARGO performed strongly.
Disclosure regarding the going concern assumption
Not applicable
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 / Excluded 0 / Company name Not applicable
Material subsequent eventsOn 2 October 2026, the Company entered into an exclusive license agreement with Italfarmaco S.p.A. covering the development and commercialization of JR-141 (pabinafusp alfa) in the United States, Europe and Latin America. The Company is entitled to receive an upfront payment, development milestones and royalties after launch.
Breakdown of extraordinary income (loss)Extraordinary income None (total: -) / Extraordinary loss Loss on disposal of property, plant and equipment ¥10 million
Depreciation and amortization¥1,081 million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for institutional investors and analysts)
Issued Shares at Period-End129,686,308 Shares
Treasury Shares at Period-End7,434,678 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥19,974 million (YoY -6.5%) |
| Operating profit | ¥-3,504 million |
| Ordinary income | ¥-3,798 million |
| Profit attributable to owners of the parent | ¥-3,867 million |
| Net income per share | -¥31.67 |
| Equity ratio | End of the current fiscal period 35.9 / End of previous period 42.9 |
| Total assets | ¥113,876 million |
| Net assets | ¥41,389 million |
| Cash flows from operating activities | ¥-3,804 million |
| Cash flows from investing activities | ¥-8,267 million |
| Cash flows from financing activities | ¥8,524 million |
| Cash and cash equivalents at end of period | ¥10,435 million |
| Full-year earnings forecast | Net Sales ¥45,700 million (YoY +13.3%) / Operating profit ¥1,100 million (YoY +98.2%) / Ordinary income ¥500 million (YoY -57.1%) / Net income ¥200 million (YoY -90.8%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | 20 Yen → 20 Yen（0.0%） |
| Depreciation and amortization | ¥1,081 million |
| Breakdown of extraordinary income (loss) | Extraordinary income None (total: -) / Extraordinary loss Loss on disposal of property, plant and equipment ¥10 million |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not applicable |
| Material subsequent events | On 2 October 2026, the Company entered into an exclusive license agreement with Italfarmaco S.p.A. covering the development and commercialization of JR-141 (pabinafusp alfa) in the United States, Europe and Latin America. The Company is entitled to receive an upfront payment, development milestones and royalties after launch. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and analysts) |
| Issued Shares at Period-End | 129,686,308 Shares |
| Treasury Shares at Period-End | 7,434,678 Shares |
| Factors Behind Changes in Business Performance | Lower contract revenue, lower revenue from Growject, and a 30.6% increase in research and development expenses. Meanwhile, IZCARGO performed strongly. |
Items this document does not state (8)
Operating MarginPayout ratioShareholder Return PolicySegment revenueSegment profitRegional salesOrders received and order backlogImpairment loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Contract revenue declined, revenue from Growject decreased, and research and development expenses increased 30.6% due to active research and development activities and progress in global clinical development.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.